Evidence map›Paper›PMID 30460985›Full record

ArticleInternational journal of dermatology2019

A retrospective review of patients with Kaposi's sarcoma in Botswana.

Christa Slaught, Victoria Williams, Surbhi Grover, Elizabeth Bigger, Mukendi Kayembe, Sebathu Chiyapo, Nicholas J Jackson, Scott Dryden-Peterson, Carrie L Kovarik, Karolyn A Wanat

Abstract read
In one paragraph

Article in International journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Christa SlaughtDepartment of Dermatology, Oregon Health and Sciences University, Portland, OR, USA.
Victoria WilliamsMinistry of Health of Botswana, Gaborone, Botswana.
Surbhi GroverDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Elizabeth BiggerDepartment of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Mukendi KayembeDepartment of Anatomical Pathology, National Health Laboratory, Gaborone, Botswana.
Sebathu ChiyapoDepartment of Oncology, Princess Marina Hospital, Gaborone, Botswana.
Nicholas J JacksonDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Scott Dryden-PetersonDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Carrie L KovarikDepartment of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Karolyn A WanatDepartment of Dermatology and Pathology, University of Iowa, Iowa City, IA, USA.
University of Pennsylvania · USBotswana Harvard AIDS Institute Partnership · BWBotswana Vaccine Institute (Botswana) · BWBrigham and Women's Hospital · USMassachusetts General Hospital · USMinistry of Health · BWOregon Health & Science University · USUniversity of California, Los Angeles · USUniversity of Iowa · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Use of Rapamycin for the Treatment of Hypertrophic Cardiomyopathy in Patients with Noonan Syndrome with Multiple Lentigines (NSML)ZIATR000012 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI OTTINGER, ELIZABETH · 2015 to 2019
$8.2M
Covid-19-related cervical cancer treatment interruption and role of neoadjuvant chemotherapyR01CA236546 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI DRYDEN-PETERSON, SCOTT · 2019 to 2023
$2.5M
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrenceK08CA230170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GROVER, SURBHI · 2019 to 2023
$1.4M
Risk factors for early morbidity and mortality of HIV-exposed uninfected infantsK23AI091434 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DRYDEN-PETERSON, SCOTT · 2012 to 2016
$659k
Clinical and Translational Science Institute Grant UL1TR000124UCLANCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS K08 CA230170NCI NIH HHS R01 CA236546NIAID NIH HHS K23 AI091434
6 · The paper itself

Abstract

backgroundDespite widespread antiretroviral coverage in Botswana, Kaposi's sarcoma (KS) remains among the most common malignancies. To date, adult KS in Botswana is not well characterized. The diagnosis relies on clinical suspicion that is often confirmed by histopathology given the implications of treatment; however, this poses a significant resource burden.

methodsWe conducted a retrospective review of the cohort of patients biopsied for possible KS at Princess Marina Hospital, the main dermatology referral site in Botswana, from September 2008 through June 2015 to describe the demographics, human immunodeficiency virus (HIV) characteristics, and clinical presentations of these patients. Histopathologic diagnoses were reviewed, and positive predictive value (PPV) was used to characterize the accuracy of clinical suspicion of KS.

resultsA total of 441 patients received 450 biopsies where KS was on the differential diagnosis, and 239 patients (54%) were ultimately diagnosed with KS. The KS cohort was more likely to be male (58% vs. 37%, P < 0.001), HIV positive (94% vs. 85%, P < 0.05), and have lower CD4 counts at the time of biopsy (274 cells/μl vs. 362 cells/μl, P < 0.05). The PPV of clinical suspicion of KS was 58%. When KS was not histopathologically diagnosed, clinically benign diseases were found in 17%, medically significant conditions requiring alternative therapies in 78%, and life-threatening diseases in 5%. DISCUSSION: Our study reinforces the risk factors in development of KS. The poor PPV supports the important role of histology in KS diagnosis to both ensure appropriate treatment and prevent overtreatment. Improved accessibility to biopsy and augmentation of local dermatopathologic services would likely improve diagnostic accuracy and treatment.

Indexed as

AdultBiopsyBotswanaFemaleHIV InfectionsHumansMaleMiddle AgedPredictive Value of TestsRetrospective StudiesRisk FactorsSarcoma, KaposiSkinSkin Neoplasms

Identifiers

PMID30460985
PMCPMC6923797
OpenAlexW2901387968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.